RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $14

RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperform and lowers the price target from $18 to $14.